CARsgen Therapeutics

CARsgen Therapeutics is a leading biopharmaceutical company dedicated to making cancer curable through innovative CAR T-cell therapies. With operations in China and the U.S., CARsgen Therapeutics focuses on developing cutting-edge treatments for hematologic malignancies and solid tumors. The company operates from its primary location at 1F, Building 2, No.466, Yindu Rd, Shanghai, Shanghai 200231, CN, and maintains additional facilities including Building 12, No.388, Yindu Road, Xuhui District, Shanghai, CN.

CARsgen Therapeutics has built an integrated cell therapy platform, boasting in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen Therapeutics is committed to addressing the major challenges of CAR T-cell therapies by continually developing novel technologies and a robust product pipeline with global rights. These advancements aim to improve safety profiles, enhance efficacy in treating solid tumors, and reduce treatment costs, ensuring broader access to life-saving therapies.

Driven by a vision to become a global biopharmaceutical leader, CARsgen Therapeutics is dedicated to bringing innovative and differentiated cell therapies to cancer patients worldwide. CARsgen Therapeutics' commitment to excellence and innovation positions it at the forefront of the biotechnology industry. We invite the manager of CARsgen Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.